Medication info
Trinam MR 2.5/1000 mg (Linagliptin, Metformin)

Trinam MR 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
This medication is a pale yellow oval extended-release film-coated tablet.
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401580 · Approved 2024.06.28 · Insurance code 694004280

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredient. If a patient repeatedly reports finding this medicine in their stool, the healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is taken in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes using both linagliptin and metformin. It effectively improves blood sugar levels and assists in diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredient. If a patient repeatedly reports finding this medicine in their stool, the healthcare professional should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication can cause serious lactic acidosis and hypoglycemia, so caution is required. Particularly, patients allergic to any component of this medication or those with type 1 diabetes, severe renal impairment, or liver dysfunction should not use it. Administration should be avoided in cases of dehydration, severe infections, heart failure, acute myocardial infarction, or any condition that may affect kidney function. When taking this medication, caution is required when used in combination with other hypoglycemic agents to reduce the risk of hypoglycemia, and blood sugar levels should be monitored frequently. Lactic acidosis is rare but a very dangerous side effect; if symptoms such as abdominal pain, muscle pain, lethargy, or difficulty breathing occur, immediate medical attention should be sought. If kidney function is decreased, regular kidney function tests should be conducted and medication dosage adjusted accordingly. During surgery or radiological examinations, this medication should be temporarily discontinued and restarted after kidney function has recovered. Acute pancreatitis or vesicular skin diseases may occur; if severe abdominal pain or skin abnormalities arise during use, stop the medication immediately and consult a doctor. This medication should not be chewed, broken, or crushed but swallowed whole, and the tablet shell may appear in the stool, which is normal. Vitamin B12 deficiency may occur, so if taken for a long time, it is advisable to regularly check blood vitamin B12 levels. It is preferable to avoid using this medication during pregnancy or breastfeeding; patients planning to conceive should consult a physician. Elderly patients may have decreased kidney function, so dosage adjustments and regular kidney function tests are necessary. There may be interactions with other medications, so if other medications are being taken, it is essential to inform a physician or pharmacist. In cases of overdose, intervention may be required to remove the drug from the gastrointestinal tract or blood dialysis, so immediate medical attention is necessary. Finally, keep this medication out of the reach of children and store it in a dry place.

Side effects

Lactic acidosis, hypoglycemia, taste disturbance, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, angioedema, urticaria, pruritus, erythema, rash, similar to pemphigus vulgaris, severe joint pain accompanied by disability, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reaction, abnormal vitamin B12 absorption test, angioedema, increased triglycerides in the blood, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, nausea, gastroesophageal reflux disease, gastritis, viral upper respiratory tract infection, upper respiratory tract infection, periodontitis, dizziness, sensory impairment, chest discomfort, weakness, nosebleed, oropharyngeal pain, voice disorders, epistaxis, male pattern baldness, hyperhidrosis, hair loss, dermatitis, anxiety, mood disorders, insomnia, depression, hypertension, hearing loss, erectile dysfunction, goiter, confusional state, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a closed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's efficacy and safety for an extended period.

Appearance and packaging

Appearance

This medication is a pale yellow oval extended-release film-coated tablet.

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.